Results 11 to 20 of about 1,016,101 (284)

Chimeric antigen receptors that trigger phagocytosis [PDF]

eLife, 2018
Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity and suggests that applying CAR strategies to other immune cell lineages may
Meghan A Morrissey, Adam P Williamson, Adriana M Steinbach, Edward W Roberts, Nadja Kern, Mark B Headley, Ronald D Vale   +6 more
doaj   +2 more sources

Conditionally Replicating Vectors Mobilize Chimeric Antigen Receptors against HIV

Molecular Therapy: Methods & Clinical Development, 2020
Human immunodeficiency virus (HIV) is an attractive target for chimeric antigen receptor (CAR) therapy. CAR T cells have proved remarkably potent in targeted killing of cancer cells, and we surmised that CAR T cells could prove useful in eradicating HIV ...
Ryan Z. Urak, Citradewi Soemardy, Roslyn Ray, Shirley Li, Galina Shevchenko, Tristan Scott, Laura Lim, Xiuli Wang, Kevin V. Morris   +8 more
doaj   +2 more sources

Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity

Cells, 2021
T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric antigen ...
John T. Keane, Avery D. Posey
doaj   +2 more sources

Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors

Molecular Therapy: Oncolytics, 2016
Chimeric antigen receptors (CARs) are used to redirect effector cell specificity to selected cell surface antigens. Using CARs, antitumor activity can be initiated in patients with no prior tumor specific immunity.
Robert Moot, Sunil S Raikar, Lauren Fleischer, Melissa Querrey, Daniel E Tylawsky, Hirotomo Nakahara, Christopher B Doering, H Trent Spencer   +7 more
doaj   +2 more sources

Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors [PDF]

, 2022
Chimeric antigen receptors (CARs) can redirect T cells to target abnormal cells, but their activity is limited by a profound defect in antigen sensitivity, the source of which remains unclear.
Pettmann, Johannes, Dushek, Omer, Salzer, Benjamin, Kutuzov, Mikhail, Siller-Farfan, Jesús, Burton, Jake, Van Der Merwe, P Anton   +6 more
core   +1 more source

Hyperstabilization of T cell microvilli contacts by chimeric antigen receptors [PDF]

, 2023
T cells typically recognize their ligands using a defined cell biology-the scanning of their membrane microvilli (MV) to palpate their environment-while that same membrane scaffolds T cell receptors (TCRs) that can signal upon ligand binding.
Marchuk, Kyle, Roybal, Kole T, Sriram, Venkataraman, Castellanos, Carlos A, Eichorst, John, Cai, En, Beppler, Casey, Krummel, Matthew F   +7 more
core   +1 more source

CAR-T cell therapy for hematological malignancies: History, status and promise

Heliyon, 2023
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis.
Chao Wang, Jianpeng Wang, Shusheng Che, Hai Zhao   +3 more
doaj   +1 more source

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor, Johannessen, Ingolfur, Talbot, Simon, Cheadle, Eleanor J, Crawford, Dorothy, Gilham, David, Gilham, David E, Johannessen, Ingo, Swanson, Anna   +8 more
core   +1 more source

Engineering Chimeric Antigen Receptors [PDF]

Acta Naturae, 2017
Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens.
S V, Kulemzin, V V, Kuznetsova, M, Mamonkin, A V, Taranin, A A, Gorchakov   +4 more
openaire   +2 more sources

Chimeric Antigen Receptors for T-Cell Malignancies

Frontiers in Oncology, 2019
Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed
Lauren D. Scherer, Lauren D. Scherer, Malcolm K. Brenner, Malcolm K. Brenner, Malcolm K. Brenner, Maksim Mamonkin, Maksim Mamonkin, Maksim Mamonkin, Maksim Mamonkin   +8 more
doaj   +1 more source